You're a year late.
VZ spotted the trend this time last year, and that was way before Putin invaded Ukraine.
~vz
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
VZ spotted the trend this time last year, and that was way before Putin invaded Ukraine.
Thanks VZ.
Funny you mentioned Purple... I did a refit of my place with new beds earlier this year.
Instead, I picked up some Dormeo Toppers. OMFG!
The current Purple TV ad in my area is cute!
Boo-hooooo... no one ever thanks me.
Well, he did admit he was drinking. But I trust this rally as far as I can throw Stoney, which is not far. We need to see capitulation bottom in the indices before I think about getting into another long position.
Earnings season is starting in two weeks. Oh my. We shall see!
Stoned One's Rally set to continue; Nasdaq, S&P, Dow futures jump as 2-year yield tests 4%
Oct. 04, 2022 6:10 AM ETS&P 500 Futures (SPX)INDU, US10Y, US2Y
Stock index futures point to continued strength Tuesday following as strong rally predicted by gummybear advisors in the previous session to kick off the fourth quarter, with rates continuing to decline.
Nasdaq 100 futures (NDX:IND) +1.9%, S&P futures (SPX) +1.5% and Dow futures (INDU) +1.2% are rallying.
Renewed buying has seen speculation of a stock market bottom rising and hopes more dovish global central banks can underpin gains.
Oct. 04, 2022 6:10 AM ETS&P 500 Futures (SPX)INDU, US10Y, US2Y
Stock index futures point to continued strength Tuesday following as strong rally predicted by gummybear advisors in the previous session to kick off the fourth quarter, with rates continuing to decline.
Nasdaq 100 futures (NDX:IND) +1.9%, S&P futures (SPX) +1.5% and Dow futures (INDU) +1.2% are rallying.
Renewed buying has seen speculation of a stock market bottom rising and hopes more dovish global central banks can underpin gains.
--Amazon remains JPMorgan's top internet idea, followed by Uber
BUY UBER-$26.70
--LG Display upgraded to Overweight from Underweight at Morgan Stanley 07:06 LPL Morgan Stanley analyst Shawn Kim upgraded LG Display to Overweight from Underweight with a price target of KRW 17,000, up from KRW 13,000. With the LCD TV panel cycle inflecting, and IT panels "close to the bottom," he argues the "time to buy is now."
BUY LG (LPL) $4.20
--Zymeworks assumed with an Overweight at Wells Fargo 06:57 ZYME
BUY ZYME $5.95
Alaunos Therapeutics assumed with an Overweight at Wells Fargo » 06:49 TCRT
TFI International initiated with an Overweight at Wells Fargo 06:46 TFII Wells Fargo analyst James Monigan initiated coverage of TFI International with an Overweight rating and $111 price target given his belief that estimates are too low and the current multiple reflects underappreciated earnings power. His view is that cost take-out at TForce Freight and buybacks can drive a 50% increase in 2024 EPS versus 2021. In addition, a robust free cash flow profile provides optionality for either more significant share repurchases, or significant M&A, providing a valuation buttress, Monigan notes. Given the cyclical headwinds, the analyst believes TFI's idiosyncratic self-help story can outperform on the back of 1,000bps of margin expansion potential at US LTL, the ability to execute a 10% share repurchase, and the potential for significant M&A.
WATCH-
TCRT & TFII
BUY UBER-$26.70
--LG Display upgraded to Overweight from Underweight at Morgan Stanley 07:06 LPL Morgan Stanley analyst Shawn Kim upgraded LG Display to Overweight from Underweight with a price target of KRW 17,000, up from KRW 13,000. With the LCD TV panel cycle inflecting, and IT panels "close to the bottom," he argues the "time to buy is now."
BUY LG (LPL) $4.20
--Zymeworks assumed with an Overweight at Wells Fargo 06:57 ZYME
BUY ZYME $5.95
Alaunos Therapeutics assumed with an Overweight at Wells Fargo » 06:49 TCRT
TFI International initiated with an Overweight at Wells Fargo 06:46 TFII Wells Fargo analyst James Monigan initiated coverage of TFI International with an Overweight rating and $111 price target given his belief that estimates are too low and the current multiple reflects underappreciated earnings power. His view is that cost take-out at TForce Freight and buybacks can drive a 50% increase in 2024 EPS versus 2021. In addition, a robust free cash flow profile provides optionality for either more significant share repurchases, or significant M&A, providing a valuation buttress, Monigan notes. Given the cyclical headwinds, the analyst believes TFI's idiosyncratic self-help story can outperform on the back of 1,000bps of margin expansion potential at US LTL, the ability to execute a 10% share repurchase, and the potential for significant M&A.
WATCH-
TCRT & TFII
FUTURES UP 1.5%! 
THAT'S THE " OVERNIGHT " FUTURES.... Ironic.....
--Thermo King completes initial testing of evolve electric trailer 06:37 TT Thermo King has completed…
--Citi opens 'catalyst watch' on Schlumberger into analyst day 06:21 SLB Citi analyst Scott Gruber opened a positive "catalyst watch" on shares of Schlumberger into the company's November 3 analyst day. He keeps a Buy rating on the shares with a $50 price target. Gruber thinks a "sufficiently bullish narrative" with respect to its digital business growth and the "resiliency" of the international oilfield services growth cycle should "propel the stock." Combined, these drivers should propel Schlumberger's EBITDA up 50% through 2025, Gruber tells investors in a research note. He believes such growth trumps the company's capital return framework.
THAT'S THE " OVERNIGHT " FUTURES.... Ironic..... --Thermo King completes initial testing of evolve electric trailer 06:37 TT Thermo King has completed…
--Citi opens 'catalyst watch' on Schlumberger into analyst day 06:21 SLB Citi analyst Scott Gruber opened a positive "catalyst watch" on shares of Schlumberger into the company's November 3 analyst day. He keeps a Buy rating on the shares with a $50 price target. Gruber thinks a "sufficiently bullish narrative" with respect to its digital business growth and the "resiliency" of the international oilfield services growth cycle should "propel the stock." Combined, these drivers should propel Schlumberger's EBITDA up 50% through 2025, Gruber tells investors in a research note. He believes such growth trumps the company's capital return framework.
Banks- Better buy em'
Citi opens 'positive catalyst watch' on JPMorgan into results 06:00 JPM Citi analyst Keith Horowitz opened a "positive catalyst watch" on shares of JPMorgan into the company's Q3 results and keeps a Buy rating on the shares with a $135 price target. The analyst believes a Q3 beat on sales will lead to upward revisions on full year guidance and imply a better run-rate into 2023.
BUY JPM- $107.75
Citi opens 'positive catalyst watch' on JPMorgan into results 06:00 JPM Citi analyst Keith Horowitz opened a "positive catalyst watch" on shares of JPMorgan into the company's Q3 results and keeps a Buy rating on the shares with a $135 price target. The analyst believes a Q3 beat on sales will lead to upward revisions on full year guidance and imply a better run-rate into 2023.
BUY JPM- $107.75
--Vodafone upgraded to Outperform from Neutral at Oddo BHF 05:36 VOD
--Inotiv initiated with a Buy at Jefferies 05:33 NOTV Jefferies analyst David Windley initiated coverage of Inotiv with a Buy rating and $27 price target. The analyst says acquisitions are transforming the company into a multi-service discovery and preclinical contract research organization, lifting it into the middle market "void" that has been left by the consolidation of competitors. Inotiv's acquisition of Envigo has vertically integrated its animal model supply at a time when non-human primates are undersupplied, Windley tells investors in a research note.
BUY NOTV- $17.75
--Inotiv initiated with a Buy at Jefferies 05:33 NOTV Jefferies analyst David Windley initiated coverage of Inotiv with a Buy rating and $27 price target. The analyst says acquisitions are transforming the company into a multi-service discovery and preclinical contract research organization, lifting it into the middle market "void" that has been left by the consolidation of competitors. Inotiv's acquisition of Envigo has vertically integrated its animal model supply at a time when non-human primates are undersupplied, Windley tells investors in a research note.
BUY NOTV- $17.75
Australia has led the way going .25 BP not .50-- Peak world rates // Peak Dollar on the way.
Another thing Australia and other fed banks did that ours did not is admit their fault<------
This is something our Fed should do, admit they kept rates too low for too long and stoked inflation. take some damn responsibility!
Another thing Australia and other fed banks did that ours did not is admit their fault<------
This is something our Fed should do, admit they kept rates too low for too long and stoked inflation. take some damn responsibility!
--Core Scientific initiated with an Overweight at Barclays 05:27 CORZ Barclays analyst Ramsey El-Assal initiated coverage of Core Scientific with an Overweight rating and $3 price target. The analyst says the company is positioned to benefit as the "crypto Winter" becomes "Spring." El-Assal is positive on the long-term viability of bitcoin and considers Core Scientific as among the highest quality mining assets. He views the company as a leveraged play on the crypto ecosystem.
--Glaukos initiated with a Buy at Needham 06:16 GKOS Needham analyst David Saxon initiated coverage of Glaukos with a Buy rating and $66 price target.
--Bolt Biotherapeutics initiated with a Buy at H.C. Wainwright 06:05 BOLT H.C. Wainwright analyst Edward White initiated coverage of Bolt Biotherapeutics with a Buy rating and $8 price target. Bolt is a clinical stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, White tells investors in a research note. The analyst says the company has an innovative approach to immunotherapy and a cash runway to fund key milestones through 2025.
BUY BOLT-$1.50
--Glaukos initiated with a Buy at Needham 06:16 GKOS Needham analyst David Saxon initiated coverage of Glaukos with a Buy rating and $66 price target.
--Bolt Biotherapeutics initiated with a Buy at H.C. Wainwright 06:05 BOLT H.C. Wainwright analyst Edward White initiated coverage of Bolt Biotherapeutics with a Buy rating and $8 price target. Bolt is a clinical stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, White tells investors in a research note. The analyst says the company has an innovative approach to immunotherapy and a cash runway to fund key milestones through 2025.
BUY BOLT-$1.50